Denileukin diftitox: a novel immunotoxin

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma

1997 • 2,405 citations

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

2008 • 1,928 citations

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

2005 • 1,596 citations

Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

2001 • 612 citations

The IL-2 Receptor Complex: Its Structure, Function, and Target Genes

1993 • 601 citations

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.

1990 • 436 citations

Non-Hodgkin's lymphoma

1995 • 342 citations

Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma

2005 • 293 citations

Depletion of CD4⁺CD25⁺ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro

2007 • 244 citations

Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential

2005 • 239 citations

Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2

1998 • 188 citations

Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor

1992 • 159 citations

Transient T cell depletion causes regression of melanoma metastases

2008 • 153 citations

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

2006 • 135 citations

Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor

1992 • 121 citations

DAB389IL-2 (ONTAK): A Novel Fusion Toxin Therapy for Lymphoma

2000 • 120 citations

Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

2004 • 96 citations

A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB389IL-2) in patients with severe psoriasis

2001 • 70 citations

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines

2009 • 67 citations

Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease

2005 • 60 citations

Denileukin diftitox: a concise clinical review

2005 • 59 citations

Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia

2006 • 48 citations

The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs

2006 • 45 citations

DAB₃₈₉IL2 (ONTAK^®) fusion protein therapy of chronic lymphocytic leukaemia

2003 • 43 citations

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B‐cell non‐Hodgkin lymphoma

2007 • 32 citations

Denileukin Diftitox and Hyper-CVAD in the Treatment Human T-Cell Lymphotropic Virus 1–Associated Adult T-Cell Leukemia/Lymphoma

2003 • 31 citations

DAB389IL-2 (Denileukin Diftitox, ONTAK): Review of Clinical Trials to Date

2000 • 21 citations

Cutaneous γ/δ T-Cell Lymphoma Treated with Radiation and Denileukin Diftitox

2008 • 17 citations

De novo maintenance therapy with denileukin diftitox (Ontak®) in a patient with peripheral T‐cell lymphoma is associated with prolonged remission

2008 • 14 citations

DAB389IL-2 (Denileukin Diftitox, ONTAK): Other Potential Applications

2000 • 14 citations

Enhanced interleukin-2 diphtheria toxin conjugate-induced growth suppression in retinoic acid-treated hypoxic hepatocellular carcinoma cells

2008 • 6 citations

A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

2005 • 6 citations

Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin’s lymphoma: E1497 final report

2005 • 2 citations